Novartis AG’s new heart failure drug Entresto is on track to be approved for use in Europe by the end of the year after it received the backing of EU regulators, the company said on Friday.   Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are […]

Eli Lilly and Co’s new Jardiance pill slashed deaths by 32 percent in a study of 7,000 patients with type 2 diabetes at risk of heart attack and stroke, a finding that researchers said could make it a mainstay diabetes treatment. “This is the first diabetes therapy to show robust effect in reducing cardiovascular death. […]

Novartis AG’s (NVS -1.46 %) new heart-failure treatment should cost about 17% less than what the company is charging in the U.S. because wide use of the drug would strain health-care budgets, a nonprofit research group said Friday. Entresto’s U.S. list price, also known as its wholesale acquisition cost, is $12.50 a day, or about […]

A new Novartis AG drug to treat heart failure should cost 17 percent less than its list price of $4,560 per year to keep health costs in line with growth in the overall U.S. economy, according to the nonprofit ICER. In a draft report released on Friday, the Boston-based Institute for Clinical and Economic Review […]

Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial. Having done well with recently launched drugs like stroke prevention pill Xarelto and eye treatment Eylea, the German group is eager to […]

Medtronic To Acquire Twelve, Developer Of Transcatheter Mitral Valve Replacement Device DUBLIN – August 25, 2015 – In support of the company’s therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. (“Twelve”), a privately-held medical device company based in Redwood City, Calif., focused on […]

Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too much. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk […]

St. Jude Medical Inc (STJ.N) agreed to buy smaller rival Thoratec Corp (THOR.O) for about $3.4 billion, giving it more devices for patients with the highest risk of heart failure. St. Jude said on Wednesday it would offer $63.50 per Thoratec share, which represents a premium of about 10 percent to the stock’s Tuesday close. […]

The U.S. food and Drug Administration said it was strengthening an existing warning label that non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. NSAIDs are used to treat pain and fever from medical conditions such as arthritis, menstrual cramps, headaches, colds, and the flu, and some of the better-known […]

The Food and Drug Administration strengthened its safety warnings about heart-attack and stroke risks linked to a class of common pain relievers that includes medicines such as Celebrex, Advil, Motrin IB and Aleve. The FDA said new data have caused it to conclude that the medicines—called NSAIDs, for nonsteroidal anti-inflammatory drugs—definitely cause an increased risk […]